Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses

J Clin Invest. 2024 May 1;134(9):e181575. doi: 10.1172/JCI181575.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Published Erratum

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Eukaryotic Initiation Factor-4E* / genetics
  • Eukaryotic Initiation Factor-4E* / metabolism
  • Humans
  • Intracellular Signaling Peptides and Proteins* / genetics
  • Intracellular Signaling Peptides and Proteins* / immunology
  • Intracellular Signaling Peptides and Proteins* / metabolism
  • Melanoma* / genetics
  • Melanoma* / immunology
  • Melanoma* / metabolism
  • Melanoma* / pathology
  • Mice
  • Phenotype
  • Protein Serine-Threonine Kinases* / genetics
  • Protein Serine-Threonine Kinases* / immunology
  • Protein Serine-Threonine Kinases* / metabolism

Substances

  • Protein Serine-Threonine Kinases
  • Intracellular Signaling Peptides and Proteins
  • Eukaryotic Initiation Factor-4E
  • MKNK1 protein, human
  • MAP-kinase-activated kinase 2